LightPath Technologies Reports Third Quarter Fiscal 2025 Financial Results
Financial Summary:
|
Three Months Ended |
|
||
$ in millions |
2025 |
2024 |
% Change |
|
Revenue |
|
|
19.1 % |
|
Gross Profit |
|
|
65.9 % |
|
Operating Expenses |
|
|
42.9 % |
|
Net Income (Loss) |
( |
( |
37.1 % |
|
Adj. EBITDA* (non-GAAP) |
( |
( |
(31.3 %) |
|
|
|
|
|
|
Third Quarter Fiscal 2025 & Subsequent Highlights:
- Closed the acquisition of G5 Infrared ("G5"), a leading high-end infrared camera systems manufacturer, part of LightPath's strategic vision to become a leading vertically-integrated infrared imaging solutions provider.
- Awarded an initial
$2.2 million engineering development model (EDM) order for infrared cameras by L3Harris Technologies to support theNavy's Shipboard Panoramic Electro-Optic/Infrared (SPEIR) Program. - Received a
$4.8 million initial qualification order for infrared cameras with a new defense industry customer, for planned delivery in calendar year 2025. - Secured
$4.9 million order for cooled infrared cameras with existing defense customer, for planned delivery in fiscal 2026. - Participated in leading industry and investor conferences including the Photonics Spectra Infrared Imaging Summit 2025, SPIE Defense + Commercial Sensing, Advanced Infrared Solutions at 2025 Border Security Expo, 27th Annual
Needham Growth Conference , and Sequire Investor Summit Puerto Rico.
Management Commentary
"G5's significant pipeline of new business opportunities, with multiple program awards expected to begin production in the next two years, was highlighted recently by three new orders that validate our accretive acquisition. A
"Looking ahead, we expect continued momentum for our product portfolio and market potential with our Germanium-free BlackDiamond™ infrared imaging solutions. With supply chain issues plaguing competing Germanium based solutions – such as
"We are moving forward with key defense programs, including our bid to produce a design of a major missile program for the
Third Quarter Fiscal 2025 Financial Results
Revenue for the third quarter of fiscal 2025 increased 19.1% to
Product Group Revenue |
Third Quarter of |
Third Quarter of |
% Change |
Infrared Components |
|
|
0 % |
Visible Components |
|
|
6 % |
Assemblies & Modules |
|
|
123 % |
|
|
|
54 % |
** Numbers may not foot due to rounding
Gross profit increased 65.9% to
Operating expenses increased 42.9% to
Net loss in the third quarter of fiscal 2025 totaled
Adjusted EBITDA* loss for the third quarter of fiscal 2025 was
Third Quarter Fiscal 2025 Earnings Call
Management will host an investor conference call at
Date:
Time:
International Dial-in: 1-201-389-0878
Conference ID: 13749941
Webcast: LPTH Q3 FY2025 Earnings Conference Call
Please join at least five minutes before the start of the call to ensure timely participation.
A playback of the call will be available through
About
*Use of Non-GAAP Financial Measures
To provide investors with additional information regarding financial results, this press release includes references to EBITDA and adjusted EBITDA, which are non-GAAP financial measures. The Company calculates EBITDA by adjusting net income to exclude net interest expense, income tax expense or benefit, depreciation, and amortization. We also calculate adjusted EBITDA, which excludes: (1) the effect of the non-cash income or expense associated with the mark-to-market adjustments, related to the warrants; and (2) the loss on extinguishment of debt. The fair value of the warrants is re-measured each reporting period until the warrants are either exercised or expired (which expiration occurs on
A "non-GAAP financial measure" is generally defined as a numerical measure of a company's historical or future performance that excludes or includes amounts, or is subject to adjustments, so as to be different from the most directly comparable measure calculated and presented in accordance with GAAP. The Company's management believes that these non-GAAP financial measures, when considered together with the GAAP financial measures, provide information that is useful to investors in understanding period-over-period operating results separate and apart from items that may, or could, have a disproportionately positive or negative impact on results in any particular period. Management also believes that these non-GAAP financial measures enhance the ability of investors to analyze underlying business operations and understand performance. In addition, management may utilize these non-GAAP financial measures as guides in forecasting, budgeting, and planning. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures presented in accordance with GAAP. A reconciliation of these non-GAAP financial measures with the most directly comparable financial measures calculated in accordance with GAAP is presented in the table below.
|
|
|||||||||||||||
|
|
|||||||||||||||
|
|
(unaudited) |
|
|||||||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net loss |
|
$ |
(3,560,349) |
|
|
$ |
(2,597,534) |
|
|
$ |
(7,795,091) |
|
|
$ |
(5,653,573) |
|
Depreciation and amortization |
|
|
1,463,150 |
|
|
|
1,042,850 |
|
|
|
3,356,752 |
|
|
|
2,985,850 |
|
Income tax provision |
|
|
100,031 |
|
|
|
5,798 |
|
|
|
160,192 |
|
|
|
121,402 |
|
Interest expense |
|
|
498,862 |
|
|
|
37,649 |
|
|
|
817,275 |
|
|
|
149,048 |
|
EBITDA |
|
$ |
(1,498,306) |
|
|
$ |
(1,511,237) |
|
|
$ |
(3,460,872) |
|
|
$ |
(2,397,273) |
|
Loss on extinguishment of debt |
|
|
418,502 |
|
|
|
|
|
|
|
418,502 |
|
|
|
|
|
Change in fair value of warrant liability |
|
|
(904,694) |
|
|
|
|
|
|
|
(904,694) |
|
|
|
|
|
Adjusted EBITDA |
|
$ |
(1,984,498) |
|
|
$ |
(1,511,237) |
|
|
$ |
(3,947,064) |
|
|
$ |
(2,397,273) |
|
% of revenue |
|
|
-22 |
% |
|
|
-20 |
% |
|
|
-16 |
% |
|
|
-10 |
% |
Forward-Looking Statements
This press release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "guidance," "plan," "estimate," "will," "would," "project," "maintain," "intend," "expect," "anticipate," "prospect," "strategy," "future," "likely," "may," "should," "believe," "continue," "opportunity," "potential," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, without limitation, statements regarding: (i) anticipated timing for program awards, as well as any resulting impact on our financial performance; (ii) the impact of the G5 acquisition on our business and results of operations; (iii) the performance of our product portfolio and expected market potential with our products and (iv) expectations regarding our ability to secure government and military projects with certain customers. These forward-looking statements are based on information available at the time the statements are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the impact of varying demand for the Company products; the ability of the Company to obtain needed raw materials and components from its suppliers; the impact of tariffs and other governmental trade restrictions; actions governments, businesses, and individuals take in response to the pandemic, including restrictions on onsite commercial interactions; general economic uncertainty in key global markets and a worsening of global economic conditions or low levels of economic growth; geopolitical tensions, the Russian-Ukraine conflict, and the
Condensed Consolidated Balance Sheets (unaudited) |
|
|||||||
|
|
|||||||
|
|
|
|
|
|
|
||
Assets |
|
2025 |
|
|
2024 |
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
6,478,885 |
|
|
$ |
3,480,268 |
|
Trade accounts receivable, net of allowance of |
|
|
7,651,086 |
|
|
|
4,928,931 |
|
Inventories, net |
|
|
12,687,225 |
|
|
|
6,551,059 |
|
Prepaid expenses and deposits |
|
|
1,206,115 |
|
|
|
445,900 |
|
Other current assets |
|
|
57,815 |
|
|
|
131,177 |
|
Total current assets |
|
|
28,081,126 |
|
|
|
15,537,335 |
|
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
15,461,601 |
|
|
|
15,210,612 |
|
Operating lease right-of-use assets |
|
|
6,457,530 |
|
|
|
6,741,549 |
|
Intangible assets, net |
|
|
21,476,226 |
|
|
|
3,650,739 |
|
|
|
|
9,741,473 |
|
|
|
6,764,127 |
|
Deferred tax assets, net |
|
|
123,000 |
|
|
|
123,000 |
|
Other assets |
|
|
79,860 |
|
|
|
59,602 |
|
Total assets |
|
$ |
81,420,816 |
|
|
$ |
48,086,964 |
|
Liabilities and Stockholders Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
5,737,240 |
|
|
$ |
3,231,713 |
|
Accrued liabilities |
|
|
3,079,036 |
|
|
|
1,911,867 |
|
Accrued payroll and benefits |
|
|
1,752,940 |
|
|
|
1,446,452 |
|
Operating lease liabilities, current |
|
|
1,271,740 |
|
|
|
1,059,998 |
|
Loans payable, current portion |
|
|
185,631 |
|
|
|
209,170 |
|
Finance lease obligation, current portion |
|
|
203,954 |
|
|
|
177,148 |
|
Total current liabilities |
|
|
12,230,541 |
|
|
|
8,036,348 |
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities, net |
|
|
1,498,479 |
|
|
|
326,197 |
|
Accrued liabilities, noncurrent |
|
|
937,000 |
|
|
|
611,619 |
|
Finance lease obligation, less current portion |
|
|
457,441 |
|
|
|
528,753 |
|
Operating lease liabilities, noncurrent |
|
|
7,518,766 |
|
|
|
8,058,502 |
|
Loans payable, less current portion |
|
|
4,693,544 |
|
|
|
325,880 |
|
Warrant liability |
|
|
4,116,357 |
|
|
|
|
|
Total liabilities |
|
|
31,452,128 |
|
|
|
17,887,299 |
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series G Convertible Preferred Stock; |
|
$ |
34,399,622 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Preferred stock: Series D, |
|
|
|
|
|
|
|
|
500,000 shares authorized; none issued and outstanding |
|
|
|
|
|
|
|
|
Common stock: Class A, |
|
|
|
|
|
|
|
|
94,500,000 shares authorized; |
|
|
|
|
|
|
|
|
42,893,563 and 39,254,643 shares issued and outstanding |
|
|
428,936 |
|
|
|
392,546 |
|
Additional paid-in capital |
|
|
238,327,729 |
|
|
|
245,140,758 |
|
Accumulated other comprehensive income |
|
|
451,067 |
|
|
|
509,936 |
|
Accumulated deficit |
|
|
(223,638,666) |
|
|
|
(215,843,575) |
|
Total stockholders equity |
|
|
15,569,066 |
|
|
|
30,199,665 |
|
Total liabilities, convertible preferred stock and stockholders equity |
|
$ |
81,420,816 |
|
|
$ |
48,086,964 |
|
Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) |
|
|||||||||||||||
|
|
|||||||||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
|
|
|
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Revenue, net |
|
$ |
9,167,627 |
|
|
$ |
7,699,175 |
|
|
$ |
24,992,837 |
|
|
$ |
23,092,060 |
|
Cost of sales |
|
|
6,503,526 |
|
|
|
6,092,988 |
|
|
|
17,553,476 |
|
|
|
16,985,846 |
|
Gross profit |
|
|
2,664,101 |
|
|
|
1,606,187 |
|
|
|
7,439,361 |
|
|
|
6,106,214 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
4,448,359 |
|
|
|
3,171,770 |
|
|
|
11,075,005 |
|
|
|
8,691,395 |
|
New product development |
|
|
757,938 |
|
|
|
569,962 |
|
|
|
1,998,775 |
|
|
|
1,817,598 |
|
Amortization of intangible assets |
|
|
779,025 |
|
|
|
434,403 |
|
|
|
1,469,512 |
|
|
|
1,201,120 |
|
Loss on disposal of property and equipment |
|
|
2,068 |
|
|
|
13,248 |
|
|
|
80,505 |
|
|
|
13,248 |
|
Total operating expenses |
|
|
5,987,390 |
|
|
|
4,189,383 |
|
|
|
14,623,797 |
|
|
|
11,723,361 |
|
Operating loss |
|
|
(3,323,289) |
|
|
|
(2,583,196) |
|
|
|
(7,184,436) |
|
|
|
(5,617,147) |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
(498,862) |
|
|
|
(37,649) |
|
|
|
(817,275) |
|
|
|
(149,048) |
|
Loss on extinguishment of debt |
|
|
(418,502) |
|
|
|
|
|
|
|
(418,502) |
|
|
|
|
|
Change in fair value of warrant liability |
|
|
904,694 |
|
|
|
|
|
|
|
904,694 |
|
|
|
|
|
Other income (expense), net |
|
|
(124,359) |
|
|
|
29,109 |
|
|
|
(119,380) |
|
|
|
234,024 |
|
Total other income (expense), net |
|
|
(137,029) |
|
|
|
(8,540) |
|
|
|
(450,463) |
|
|
|
84,976 |
|
Loss before income taxes |
|
|
(3,460,318) |
|
|
|
(2,591,736) |
|
|
|
(7,634,899) |
|
|
|
(5,532,171) |
|
Income tax provision |
|
|
100,031 |
|
|
|
5,798 |
|
|
|
160,192 |
|
|
|
121,402 |
|
Net loss |
|
$ |
(3,560,349) |
|
|
$ |
(2,597,534) |
|
|
$ |
(7,795,091) |
|
|
$ |
(5,653,573) |
|
Foreign currency translation adjustment |
|
|
120,572 |
|
|
|
(112,356) |
|
|
|
(58,869) |
|
|
|
22,409 |
|
Comprehensive loss |
|
$ |
(3,439,777) |
|
|
$ |
(2,709,890) |
|
|
$ |
(7,853,960) |
|
|
$ |
(5,631,164) |
|
Loss per common share (basic) |
|
$ |
(0.09) |
|
|
$ |
(0.07) |
|
|
$ |
(0.19) |
|
|
$ |
(0.15) |
|
Number of shares used in per share calculation (basic) |
|
|
41,363,643 |
|
|
|
37,988,770 |
|
|
|
40,209,657 |
|
|
|
37,639,464 |
|
Loss per common share (diluted) |
|
$ |
(0.09) |
|
|
$ |
(0.07) |
|
|
$ |
(0.19) |
|
|
$ |
(0.15) |
|
Number of shares used in per share calculation (diluted) |
|
|
41,363,643 |
|
|
|
37,988,770 |
|
|
|
40,209,657 |
|
|
|
37,639,464 |
|
Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)
|
|
|||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||
|
|
Temporary |
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|||||||||||
|
|
Series G |
|
|
Class A |
|
|
Additional |
|
|
Other |
|
|
|
|
|
Total |
|
||||||||||||||
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Paid-in |
|
|
Comprehensive |
|
|
Accumulated |
|
|
Stockholders |
|
||||||||||||||
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Income |
|
|
Deficit |
|
|
Equity |
|
||||||||
Balances at |
|
|
|
|
|
|
|
|
39,254,643 |
|
|
$ |
392,546 |
|
|
$ |
245,140,758 |
|
|
$ |
509,936 |
|
|
$ |
(215,843,575) |
|
|
$ |
30,199,665 |
|
||
Issuance of common stock for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Employee Stock Purchase Plan |
|
|
|
|
|
|
|
|
8,232 |
|
|
|
82 |
|
|
|
10,290 |
|
|
|
|
|
|
|
|
|
|
|
10,372 |
|
||
Exercise of Stock Options, RSUs & RSAs, net |
|
|
|
|
|
|
|
|
70,309 |
|
|
|
703 |
|
|
|
(703) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Issuance of common stock for acquisition of Visimid |
|
|
|
|
|
|
|
|
279,553 |
|
|
|
2,796 |
|
|
|
318,562 |
|
|
|
|
|
|
|
|
|
|
|
321,358 |
|
||
Stock-based compensation on stock options, RSUs & RSAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
264,475 |
|
|
|
|
|
|
|
|
|
|
|
264,475 |
|
||
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
271,594 |
|
|
|
|
|
|
|
271,594 |
|
||
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,622,745) |
|
|
|
(1,622,745) |
|
||
Balances at |
|
|
|
|
|
|
|
|
39,612,737 |
|
|
$ |
396,127 |
|
|
$ |
245,733,382 |
|
|
$ |
781,530 |
|
|
$ |
(217,466,320) |
|
|
$ |
29,444,719 |
|
||
Issuance of common stock for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Exercise of Stock Options, RSUs & RSAs, net |
|
|
|
|
|
|
|
|
229,097 |
|
|
|
2,291 |
|
|
|
(2,291) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Shares issued as compensation |
|
|
|
|
|
|
|
|
49,000 |
|
|
|
490 |
|
|
|
89,180 |
|
|
|
|
|
|
|
|
|
|
|
89,670 |
|
||
Stock-based compensation on stock options, RSUs & RSAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
231,581 |
|
|
|
|
|
|
|
|
|
|
|
231,581 |
|
||
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(451,035) |
|
|
|
|
|
|
|
(451,035) |
|
||
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,611,997) |
|
|
|
(2,611,997) |
|
||
Balances at |
|
|
|
|
|
|
|
|
39,890,834 |
|
|
$ |
398,908 |
|
|
$ |
246,051,852 |
|
|
$ |
330,495 |
|
|
$ |
(220,078,317) |
|
|
$ |
26,702,938 |
|
||
Issuance of preferred stock under private equity placement, net of fees |
|
|
255 |
|
|
|
20,968590 |
|
|
|
|
|
|
|
|
|
|
|
(1,320,102) |
|
|
|
|
|
|
|
|
|
|
|
(1,320,102) |
|
Issuance of common stock for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee Stock Purchase Plan |
|
|
|
|
|
|
|
|
|
|
1,137 |
|
|
|
11 |
|
|
|
4,002 |
|
|
|
|
|
|
|
|
|
|
|
4,013 |
|
Exercise of Stock Options, RSUs & RSAs, net |
|
|
|
|
|
|
|
|
|
|
238,641 |
|
|
|
2,387 |
|
|
|
788 |
|
|
|
|
|
|
|
|
|
|
|
3,175 |
|
Issuance of common stock for acquisition of Visimid |
|
|
|
|
|
|
|
|
|
|
102,700 |
|
|
|
1,027 |
|
|
|
391,561 |
|
|
|
|
|
|
|
|
|
|
|
392,588 |
|
Issuance of common stock for acquisition of G5 |
|
|
|
|
|
|
|
|
|
|
1,972,501 |
|
|
|
19,725 |
|
|
|
4,852,343 |
|
|
|
|
|
|
|
|
|
|
|
4,872,068 |
|
Issuance of common stock under private equity placement, net of fees |
|
|
|
|
|
|
|
|
|
|
687,750 |
|
|
|
6,878 |
|
|
|
1,584,014 |
|
|
|
|
|
|
|
|
|
|
|
1,590,892 |
|
Preferred cumulative dividends plus accretion |
|
|
|
|
|
|
13,431,032 |
|
|
|
|
|
|
|
|
|
|
|
(13,431,032) |
|
|
|
|
|
|
|
|
|
|
|
(13,431,032) |
|
Stock-based compensation on stock options, RSUs & RSAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
194,303 |
|
|
|
|
|
|
|
|
|
|
|
194,303 |
|
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
120,572 |
|
|
|
|
|
|
|
120,572 |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,560,349) |
|
|
|
(3,560,349) |
|
Balances at |
|
|
255 |
|
|
$ |
34,399,622 |
|
|
|
42,893,563 |
|
|
$ |
428,936 |
|
|
$ |
238,327,729 |
|
|
$ |
451,067 |
|
|
$ |
(223,638,666) |
|
|
$ |
15,569,066 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at |
|
|
|
|
|
|
|
|
|
|
37,344,739 |
|
|
$ |
373,447 |
|
|
$ |
242,808,771 |
|
|
$ |
606,536 |
|
|
$ |
(207,836,229) |
|
|
$ |
35,952,525 |
|
Issuance of common stock for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee Stock Purchase Plan |
|
|
|
|
|
|
|
|
|
|
14,607 |
|
|
|
146 |
|
|
|
19,573 |
|
|
|
|
|
|
|
|
|
|
|
19,719 |
|
Exercise of Stock Options, RSUs & RSAs, net |
|
|
|
|
|
|
|
|
|
|
14,482 |
|
|
|
145 |
|
|
|
(145) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock for acquisition of Visimid |
|
|
|
|
|
|
|
|
|
|
81,610 |
|
|
|
816 |
|
|
|
149,184 |
|
|
|
|
|
|
|
|
|
|
|
150,000 |
|
Stock-based compensation on stock options, RSUs & RSAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
240,075 |
|
|
|
|
|
|
|
|
|
|
|
240,075 |
|
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(125,208) |
|
|
|
|
|
|
|
(125,208) |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,342,376) |
|
|
|
(1,342,376) |
|
Balances at |
|
|
|
|
|
|
|
|
|
|
37,455,438 |
|
|
$ |
374,554 |
|
|
$ |
243,217,458 |
|
|
$ |
481,328 |
|
|
$ |
(209,178,605) |
|
|
$ |
34,894,735 |
|
Issuance of common stock for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of Stock Options, RSUs & RSAs, net |
|
|
|
|
|
|
|
|
|
|
93,940 |
|
|
|
940 |
|
|
|
(940) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation on stock options, RSUs & RSAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
258,691 |
|
|
|
|
|
|
|
|
|
|
|
258,691 |
|
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
259,973 |
|
|
|
|
|
|
|
259,973 |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,713,663) |
|
|
|
(1,713,663) |
|
Balances at |
|
|
|
|
|
|
|
|
|
|
37,549,378 |
|
|
$ |
375,494 |
|
|
$ |
243,475,209 |
|
|
$ |
741,301 |
|
|
$ |
(210,892,268) |
|
|
$ |
33,699,736 |
|
Issuance of common stock for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee Stock Purchase Plan |
|
|
|
|
|
|
|
|
|
|
15,840 |
|
|
|
158 |
|
|
|
19,800 |
|
|
|
|
|
|
|
|
|
|
|
19,958 |
|
Exercise of Stock Options, RSUs & RSAs, net |
|
|
|
|
|
|
|
|
|
|
225,814 |
|
|
|
2,258 |
|
|
|
(2,258) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock for acquisition of Visimid |
|
|
|
|
|
|
|
|
|
|
267,176 |
|
|
|
2,672 |
|
|
|
333,382 |
|
|
|
|
|
|
|
|
|
|
|
336,054 |
|
Issuance of common stock under public equity placement |
|
|
|
|
|
|
|
|
|
|
68,041 |
|
|
|
680 |
|
|
|
97,528 |
|
|
|
|
|
|
|
|
|
|
|
98,208 |
|
Stock-based compensation on stock options, RSUs & RSAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
264,492 |
|
|
|
|
|
|
|
|
|
|
|
264,492 |
|
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(112,356) |
|
|
|
|
|
|
|
(112,356) |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,597,534) |
|
|
|
(2,597,534) |
|
Balances at |
|
|
|
|
|
|
|
|
|
|
38,126,249 |
|
|
$ |
381,262 |
|
|
$ |
244,188,153 |
|
|
$ |
628,945 |
|
|
$ |
(213,489,802) |
|
|
$ |
31,708,558 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of Stock Options, RSUs & RSAs, net |
|
|
|
|
|
|
|
|
|
|
610,952 |
|
|
|
6,110 |
|
|
|
(6,110) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock under public equity placement |
|
|
|
|
|
|
|
|
|
|
517,442 |
|
|
|
5,174 |
|
|
|
702,950 |
|
|
|
|
|
|
|
|
|
|
|
708,124 |
|
Stock-based compensation on stock options, RSUs & RSAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
255,765 |
|
|
|
|
|
|
|
|
|
|
|
255,765 |
|
Foreign currency translation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(119,009) |
|
|
|
|
|
|
|
(119,009) |
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,353,773) |
|
|
|
(2,353,773) |
|
Balances at |
|
|
|
|
|
|
|
|
|
|
39,254,643 |
|
|
$ |
392,546 |
|
|
$ |
245,140,758 |
|
|
$ |
509,936 |
|
|
$ |
(215,843,575) |
|
|
$ |
30,199,665 |
|
Condensed Consolidated Statements of Cash Flows (unaudited) |
|
|||||||
|
|
|||||||
|
|
Nine Months Ended |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
||
Net loss |
|
$ |
(7,795,091) |
|
|
$ |
(5,653,573) |
|
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
3,356,752 |
|
|
|
2,985,850 |
|
Interest from amortization of loan issuance costs |
|
|
161,905 |
|
|
|
|
|
Loss on extinguishment of debt |
|
|
418,502 |
|
|
|
|
|
Warrant issuance costs |
|
|
318,777 |
|
|
|
|
|
Change in fair value of warrant liability |
|
|
(904,694) |
|
|
|
|
|
Loss on disposal of property and equipment |
|
|
80,505 |
|
|
|
13,248 |
|
Stock-based compensation on stock options, RSUs & RSAs, net |
|
|
745,155 |
|
|
|
763,258 |
|
Provision for credit losses |
|
|
(3,014) |
|
|
|
(4,422) |
|
Change in operating lease assets and liabilities |
|
|
(91,582) |
|
|
|
47,693 |
|
Inventory write-offs to allowance |
|
|
135,625 |
|
|
|
95,539 |
|
Deferred taxes |
|
|
(2,368) |
|
|
|
8,573 |
|
Changes in operating assets and liabilities, net of acquisitions: |
|
|
|
|
|
|
|
|
Trade accounts receivable |
|
|
(822,043) |
|
|
|
1,766,594 |
|
Other current assets |
|
|
73,362 |
|
|
|
(419,797) |
|
Inventories |
|
|
(1,206,340) |
|
|
|
725,460 |
|
Prepaid expenses and deposits |
|
|
(360,439) |
|
|
|
95,900 |
|
Accounts payable and accrued liabilities |
|
|
520,289 |
|
|
|
32,020 |
|
Net cash (used in) provided by operating activities |
|
|
(5,374,699) |
|
|
|
456,343 |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Purchase of property and equipment |
|
|
(580,726) |
|
|
|
(1,892,660) |
|
Proceeds from sale of equipment |
|
|
10,648 |
|
|
|
|
|
Proceeds from sale-leaseback of equipment |
|
|
|
|
|
|
364,710 |
|
Acquisition of G5 |
|
|
(20,250,011) |
|
|
|
|
|
Acquisition of Visimid, net of cash acquired |
|
|
|
|
|
|
(847,141) |
|
Net cash used in investing activities |
|
|
(20,820,089) |
|
|
|
(2,375,091) |
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options |
|
|
3,175 |
|
|
|
|
|
Proceeds from sale of common stock from Employee Stock Purchase Plan |
|
|
14,385 |
|
|
|
39,677 |
|
Proceeds from issuance of common stock under public equity placement |
|
|
|
|
|
|
98,208 |
|
Proceeds from issuance of common stock under private equity placement |
|
|
437,725 |
|
|
|
|
|
Proceeds from issuance of preferred stock under private equity placement |
|
|
18,842,138 |
|
|
|
|
|
Proceeds from issuance of warrants under private equity placement |
|
|
4,313,813 |
|
|
|
|
|
Deferred payment for acquisition of Visimid |
|
|
(125,000) |
|
|
|
|
|
Borrowings on loans payable |
|
|
6,659,596 |
|
|
|
142,853 |
|
Loan issuance costs |
|
|
(597,465) |
|
|
|
|
|
Payments on loans payable |
|
|
(149,118) |
|
|
|
(2,262,798) |
|
Repayment of finance lease obligations |
|
|
(133,711) |
|
|
|
(87,610) |
|
Net cash provided by (used in) financing activities |
|
|
29,265,538 |
|
|
|
(2,069,670) |
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate on cash and cash equivalents |
|
|
(72,133) |
|
|
|
2,880 |
|
Change in cash, cash equivalents and restricted cash |
|
|
2,998,617 |
|
|
|
(3,985,538) |
|
Cash, cash equivalents and restricted cash, beginning of period |
|
|
3,480,268 |
|
|
|
7,144,490 |
|
Cash, cash equivalents and restricted cash, end of period |
|
$ |
6,478,885 |
|
|
$ |
3,158,952 |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
|
|
Interest paid in cash |
|
$ |
66,136 |
|
|
$ |
161,676 |
|
Income taxes paid |
|
$ |
118,016 |
|
|
$ |
120,787 |
|
Supplemental disclosure of non-cash investing & financing activities: |
|
|
|
|
|
|
|
|
Purchase of equipment through finance lease arrangements |
|
$ |
93,048 |
|
|
$ |
391,107 |
|
Issuance of common stock for acquisition of Visimid |
|
$ |
713,946 |
|
|
$ |
486,054 |
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/lightpath-technologies-reports-third-quarter-fiscal-2025-financial-results-302456970.html
SOURCE